Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

18.79 +0.39 (+2.12%)
Streaming Delayed Price Updated: 2:34 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novocure Ltd Ord Sh

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Breaking Down NovoCure: 4 Analysts Share Their Views
Via Benzinga
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
A Closer Look at 7 Analyst Recommendations For NovoCure
Via Benzinga
Unveiling 8 Analyst Insights On NovoCure
Via Benzinga
Why NovoCure Stock Soared 18.3% This Week
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy. 
Via The Motley Fool
Why Novocure Stock Is Jumping Today
Novocure had good news mixed with some not-so-good news. 
Via The Motley Fool
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
From Novocure
Via Business Wire
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
Via Benzinga
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
NVCR stock results show that NovoCure beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
From Novocure
Via Business Wire
Novocure Reports First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to intracranial progression for NSCLC brain metastases patients compared to... 
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment
The company uses electrical fields to interrupt the rampant cellular division characteristic of cancer. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
NovoCure (NVCR) Q4 2023 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.